TG Therapeutics (TGTX) Stock Highlights

39.82 | +5.48%

2025-04-03 02:03:13

TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor.

Statistics

Range Today

37.05 42.04

Volume Today 4.49M

Range 1 Year

12.93 43.32

Volume 1 Year 770.83M

Range 3 Year

3.48 43.32

Volume 3 Year 2.92B

Range 10 Year

3.32 56.74

Volume 10 Year 5.35B

Highlights

Market Capitalization 6.26B (mid)

Floating Shares 134.54M

Current Price 39.82

Price To Earnings 268

Price To Revenue 17.57

Price To Book 25.82

Earnings Per Share 0.15

Payout Ratio 0%

Performance

Latest +5.48%

1 Month +31.29%

3 Months +30.43%

6 Months +75.88%

1 Year +175.95%

3 Years +293.48%

5 Years +347.42%

10 Years +150.44%

Benchmarks

Market Capitalization

79 / 368

Gross Profits

116 / 278

Total Revenue

61 / 300

Total Rank

360 / 368

Free Cashflow

188 / 352

Performance 5 years

26 / 368

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.